

ELOC RABBIT PAB

货号: S219187

产品全名: ELOC 兔多抗

基因符号: SIII; TCEB1

UNIPROT ID: Q15369 (Gene Accession - BC013809)

背景: This gene encodes the protein elongin C, which is a subunit of the transcription factor B (SIII) complex. The SIII complex is composed of elongins A/A2, B and C. It activates elongation by RNA polymerase II by suppressing transient pausing of the polymerase at many sites within transcription units. Elongin A functions as the transcriptionally active component of the SIII complex, whereas elongins B and C are regulatory subunits. Elongin A2 is specifically expressed in the testis, and capable of forming a stable complex with elongins B and C. The von Hippel-Lindau tumor suppressor protein binds to elongins B and C, and thereby inhibits transcription elongation. Multiple alternatively spliced transcript variants encoding two distinct isoforms have been identified.

抗原: Fusion protein of human ELOC

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-300; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 219187(ELOC Antibody) at a dilution of 1/55(Nucleus).



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the fusion protein and then with 219187(Anti-ELOC Antibody) at dilution 1/55.



The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using 219187(Anti-ELOC Antibody) at a dilution of 1/55.



In comparison with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with fusion protein and then with D226016(Anti-ELOC Antibody) at dilution 1/55.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
